Graph Safety launches on Google Cloud Marketplace

Graph AI has made its Graph Safety Suite available on Google Cloud Marketplace, expanding its work with Google Cloud and bringing AI-native pharmacovigilance tools to life sciences customers. The launch targets lower costs, faster case processing and inspection-ready workflows for pharma, biotech, CRO and healthcare teams.

Why it matters: - Graph Safety Suite is aimed at a costly part of life sciences operations: pharmacovigilance case handling and regulatory reporting. - Graph AI says the platform can cut unit costs by 66%, speed execution by 92% and reduce case turnaround time from more than 3 hours to under 10 minutes. - The Marketplace listing also lets enterprises buy through existing cloud commitments, which can simplify procurement.

What happened: - Graph AI announced the official availability of Graph Safety Suite on Google Cloud Marketplace on June 11, 2026. - The launch extends Graph AI’s collaboration with Google Cloud after graduating from the Google Cloud ISV Startup Springboard program. - The platform is built on Google Cloud infrastructure and uses Gemini Enterprise Agent Platform and Google Kubernetes Engine. - Google Cloud’s Dai Vu said the Marketplace launch will help customers deploy, manage and scale the system on Google Cloud’s global infrastructure.

The details: - Graph Safety /intake supports multi-channel ingestion and intelligent triage. - /intake can extract adverse event data from unstructured PDFs, literature feeds, CRM records and safety databases. - Graph Safety /nucleus combines generative AI with multi-algorithm causality validation for touchless case processing and a safety database. - Graph AI plans additional rollouts in 2026 for Graph Safety /report, /signal, /assure and /comply. - /report is designed for regulatory writing. - /signal is built for predictive safety surveillance. - /assure and /comply focus on QPPV governance, continuous audit readiness and dynamic risk management. - Graph AI says enterprises using the suite can achieve day-zero inspection readiness with 6 unbroken field-level provenance methods. - The company says the suite provides an unbroken, auditable citation chain for clinical reasoning at enterprise scale.

Between the lines: - Graph AI is positioning pharmacovigilance as a software problem rather than a headcount problem. - The company is pitching deterministic, inspection-ready AI as a response to manual processing models that have not kept up with growing case volumes. - The commercial rollout signals Graph AI is trying to move from startup validation to enterprise distribution across multiple regions. - The mention of mandates with pharma leaders and CROs suggests early customer traction, though the release does not name those customers.

What's next: - Graph AI plans to expand Graph Safety Suite throughout 2026 with more platform modules. - Life sciences buyers can procure the current modules immediately through Google Cloud Marketplace. - The company is directing interested buyers to learn more or calculate efficiency savings.